Ocumension Therapeutics (HKSE:01477) Total Operating Expense : HK$567.2 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Total Operating Expense?

Ocumension Therapeutics's Total Operating Expense for the six months ended in Dec. 2024 was HK$288.3 Mil. Ocumension Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was HK$567.2 Mil.

Ocumension Therapeutics Total Operating Expense Historical Data

The historical data trend for Ocumension Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Total Operating Expense Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Operating Expense

Get a 7-Day Free Trial

591.77

517.31

615.47

596.88

564.95

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Operating Expense	Get a 7-Day Free Trial								334.41	313.06	283.83	278.97	288.28

Ocumension Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$567.2 Mil.

Ocumension Therapeutics Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

5DG:Germany

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

https://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Executives

Liu Ye	2101 Beneficial owner
6 Dimensions Capital, L.p.	2101 Beneficial owner
Zhang Qiping	2201 Interest of corporation controlled by you
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
6 Dimensions Capital Gp, Llc	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Boyu Capital Fund Iv, L.p.	2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd	2201 Interest of corporation controlled by you
Summer Iris Limited	2101 Beneficial owner
Alcon Pharmaceuticals Ltd	2101 Beneficial owner
Alcon Inc.	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you

Ocumension Therapeutics Headlines

No Headlines